The Gut Hormones PYY(3-36) and GLP-1(7-36 amide) Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans

Obesity is a major public health issue worldwide. Understanding how the brain controls appetite offers promising inroads toward new therapies for obesity. Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are coreleased postprandially and reduce appetite and inhibit food intake when administered...

Descripción completa

Detalles Bibliográficos
Autores principales: De Silva, Akila, Salem, Victoria, Long, Christopher J., Makwana, Aidan, Newbould, Rexford D., Rabiner, Eugenii A., Ghatei, Mohammad A., Bloom, Stephen R., Matthews, Paul M., Beaver, John D., Dhillo, Waljit S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2011
Materias:
Short Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267038/
https://www.ncbi.nlm.nih.gov/pubmed/22000927
http://dx.doi.org/10.1016/j.cmet.2011.09.010
Descripción
Sumario:Obesity is a major public health issue worldwide. Understanding how the brain controls appetite offers promising inroads toward new therapies for obesity. Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are coreleased postprandially and reduce appetite and inhibit food intake when administered to humans. However, the effects of GLP-1 and the ways in which PYY and GLP-1 act together to modulate brain activity in humans are unknown. Here, we have used functional MRI to determine these effects in healthy, normal-weight human subjects and compared them to those seen physiologically following a meal. We provide a demonstration that the combined administration of PYY(3-36) and GLP-1(7-36 amide) to fasted human subjects leads to similar reductions in subsequent energy intake and brain activity, as observed physiologically following feeding.

Ejemplares similares